Closing Bell Movers: Shift4 down 10%, Penumbra up 8% after results
Check out this evening’s top movers from around Wall Street, compiled by The Fly.Discover the Best Stocks and Maximize Your Portfolio: See what ...
Supernus' Shares Fall 22% After Depression Study Misses Endpoint
Shares of Supernus slid after the company it failed to meet the primary endpoint in its Phase 2b study of SPN-820 in adults with treatment resistant depression.
Supernus announces SPN-820 trial misses primary endpoint
Supernus (SUPN) announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically ...
manilatimes5h
CDPQ to sell 2,500,000 common shares of Intact Financial
MONTRÉAL, Feb. 18, 2025 (GLOBE NEWSWIRE) -- CDPQ today announced its intention to sell 2,500,000 common shares of Intact Financial Corporation (TSX: IFC), representing approximately 1.4% of the issued ...
Investing6h
Supernus Pharma stock tumbles after failed depression study
The study's results are particularly noteworthy as they were part of a multi-center, randomized, double-blind, placebo-controlled trial involving approximately 250 patients across roughly 40 clinical ...
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...
Supernus' depression treatment fails mid-stage trial, shares plunge
Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 22% aftermarket.